Skip to main content
. 2005 Jul;187(14):4767–4773. doi: 10.1128/JB.187.14.4767-4773.2005

FIG. 1.

FIG. 1.

Characterization of the wild type and selected mutants of TraM. (A) Comparison of levels of TraM and its mutants by immunoblot analysis with anti-TraM antiserum when expressed from its native promoters (PtraM) or from an attenuated foreign promoter (PtraJ). N.A., not applicable. (B) Autorepression of PtraM was determined by assaying the β-galactosidase activity of cells containing pACPM24fs::lacZ and pJLM102 and its derivative pJLM105 (K99E). Complementation of pOX38-MK3 was determined by measuring the donor ability of cells containing pOX38-MK3 and pJLM102 or pJLM105. <10−7 means that there was no detectable donor ability. Negative dominance was assayed by measuring the donor ability of pOX38-Km and pJLM102 or pJLM105. pT7-4 was the vector control.